NewEdge Advisors’s abrdn Life Sciences Investors HQL Stock Holding History
Bought
Maintained
Sold
Other funds holding HQL
SCM
PCM
NIM
FHA
RCM
NewEdge Advisors's HQL Position: Q1 2026 in Review
NewEdge Advisors increased its abrdn Life Sciences Investors (HQL) stake by 18% in Q1 2026, buying an estimated $59.5K and bringing the position to 23,788 shares worth $387K. The position accounts for ﹤0.01% of the portfolio, ranked #2168.
NewEdge Advisors first reported a position in HQL in Q4 2021 and has held it in 18 quarters since. The position peaked at $438K in Q2 2025. 86 funds tracked by Wall St. Rank hold HQL as of Q1 2026.
- NewEdge Advisors held 23,788 shares of abrdn Life Sciences Investors worth $387K as of Q1 2026.
- NewEdge Advisors bought 3,562 abrdn Life Sciences Investors shares in Q1 2026, an estimated $59.5K.
- abrdn Life Sciences Investors made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #2168 holding.
- NewEdge Advisors first reported a position in abrdn Life Sciences Investors in Q4 2021 and has held it in 18 quarters since.
- NewEdge Advisors's abrdn Life Sciences Investors position peaked at $438K in Q2 2025.
- 86 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2026.
Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.